{
    "organizations": [],
    "uuid": "2250e764aca60b435887d2d94c62ac587aa8101c",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/01/globe-newswire-oncomed-pharmaceuticals-to-report-first-quarter-2018-financial-results-and-operational-highlights-on-may-8th-2018.html",
    "ord_in_thread": 0,
    "title": "OncoMed Pharmaceuticals to Report First Quarter 2018 Financial Results and Operational Highlights on May 8th, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "REDWOOD CITY, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8 th , 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.\nAbout OncoMed Pharmaceuticals\nOncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com .\nInvestor Relations Contact:\nMatthew Beck\nSolebury Trout\nmbeck@troutgroup.com\n(646) 378-2933\nSource:OncoMed Pharmaceuticals, Inc.",
    "published": "2018-05-01T15:30:00.000+03:00",
    "crawled": "2018-05-01T19:13:11.027+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "redwood",
        "city",
        "may",
        "globe",
        "newswire",
        "oncomed",
        "pharmaceutical",
        "nasdaq",
        "omed",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "novel",
        "therapeutic",
        "today",
        "announced",
        "company",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "operational",
        "highlight",
        "tuesday",
        "may",
        "th",
        "oncomed",
        "conducting",
        "conference",
        "call",
        "conjunction",
        "earnings",
        "release",
        "oncomed",
        "pharmaceutical",
        "oncomed",
        "pharmaceutical",
        "biopharmaceutical",
        "company",
        "focused",
        "discovering",
        "developing",
        "novel",
        "therapeutic",
        "oncomed",
        "internally",
        "discovered",
        "broad",
        "pipeline",
        "investigational",
        "drug",
        "intended",
        "address",
        "fundamental",
        "biology",
        "driving",
        "cancer",
        "growth",
        "resistance",
        "recurrence",
        "metastasis",
        "navicixizumab",
        "bispecific",
        "rosmantuzumab",
        "part",
        "oncomed",
        "strategic",
        "alliance",
        "celgene",
        "corporation",
        "oncomed",
        "independently",
        "developing",
        "well",
        "continuing",
        "pursue",
        "new",
        "drug",
        "discovery",
        "research",
        "information",
        "oncomed",
        "pharmaceutical",
        "please",
        "see",
        "investor",
        "relation",
        "contact",
        "matthew",
        "beck",
        "solebury",
        "trout",
        "mbeck",
        "source",
        "oncomed",
        "pharmaceutical",
        "inc"
    ]
}